

TESTOPLUS

Each ml contains :
Testosterone Propionate B.P. 30mg,
Testosterone Phenylpropionate B.P. 60mg,
Testosterone Decanoate B.P. 100mg,
Oil Base q.s.

Indications and usage:
Sustanon is used to replace testosterone in the body to treat various male sexual problems, for example -
- after castration or a similar problem called eunuchoidism
- impotence caused by hormonal disorder
- decreased sex drive
- low test caused by low sperm count
- when the pituitary gland can not work as well as it should
- hypogonadotropic hypogonadism (congenital or acquired)
This can cause decreased sexual ability in males.
Sustanon may also be used as supportive therapy for female-to-male transsexuals.

Contraindications:
1. Known hypersensitivity to the drug.
2. Males with carcinoma of the breast.
3. Males with known or suspected carcinoma of the prostate gland.
4. Women who are or who may become pregnant.
5. Patients with serious cardiac, hepatic or renal disease.

Drug Interactions:
Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinaemia. Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

Overdosage:
There have been no reports of acute overdosage.

Precautions:
General: Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized. Sustanon is not for intravenous use.

Information for patients: Patients should be instructed to report any of the following: nausea, vomiting, changes in skin colour, ankle swelling, too frequent or persistent erections of the penis. Laboratory tests: Haemoglobin and haematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long term androgen administration. Serum cholesterol may increase during androgen therapy. Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Carcinogenesis:
There are rare reports of hepatocellular carcinoma in patients receiving long term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumours in all cases. Genitalic patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.

Pregnancy: Teratogenic Effects, Pregnancy Category X.



TESTOP P

Each ml contains :
Testosterone Propionate USP 100mg,
Oil Base q.s.

Indications and usage:
Males

Testosterone Propionate is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.
A Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral testis, orchitis, vanishing testis syndrome, or orchidectomy.
Hypogonadotropic hypogonadism (Congenital or acquired) -diopathic gonadotropin or LH-RH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
Females:
Testosterone Propionate may be used secondarily in women with advancing or operable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal.
Testosterone Propionate has been used for the management of postpartum breast pain and engorgement.
Contraindications:
1. Known hypersensitivity to the drugs.
2. Males with carcinoma of the breast.
3. Males with known or suspected carcinoma of the prostate gland.
4. Women who are or who may become pregnant.
5. Patients with serious cardiac, hepatic or renal disease.

Warnings:
Hypocalcaemia may occur in immobilized patients. If this occurs, the drug should be discontinued. Prolonged use of high doses of androgens, principally the 17-delta alkyl-androgens) has been associated with development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis-all potentially life-threatening complications.
Genitalic patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

Overdosage:
There have been no reports of acute overdosage with the anabolic drug.

Precautions:
General: Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized. Sustanon is not for intravenous use.
Information for patients: Patients should be instructed to report any of the following: nausea, vomiting, changes in skin colour, ankle swelling, too frequent or persistent erections of the penis. Laboratory tests: Haemoglobin and haematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long term androgen administration. Serum cholesterol may increase during androgen therapy. Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Supplied / Storage:
Testosterone Propionate is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.



Each ml contains :
Stanozolol USP 50 mg,
Benzyl Alcohol NF 0.9 % w/v,
Water for Injection USP q.s.

Indications and usage:
Winrol is used in the treatment of hereditary angioedema, which causes episodic swelling of the face, extremities, genitals, lower leg, and throat. Winrol may decrease the frequency and severity of these attacks.

Contraindications:
1. Known hypersensitivity to the drug.
2. Women who are or who may become pregnant.
3. Patients with serious cardiac, hepatic or renal disease.
4. Patients with prostatic or breast cancer.

Warnings:
Metabolic effects occurring during anabolic steroid therapy in immobilized patients or those with metastatic breast disease include osteoporosis, hypocalcaemia, hypokalaemia, hypomagnesaemia, and urinary calcium excretion. Edema, with and without congestive heart failure, has occurred during anabolic steroid therapy. The androgenic activity of anabolic steroids may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
Significant increases in low-density lipoproteins (LDL) and decreases in high-density lipoproteins (HDL) have occurred.

Renal:
Anabolic steroids cause retention of nitrogen, sodium, potassium, chloride, water and phosphorus, and decrease urinary excretion of calcium. Patients should be instructed to report edema.

Gastrointestinal:
Gastrointestinal effects occurring during stanozolol (the active ingredient contained in Winrol) therapy include nausea and vomiting.

Dosage and administration:
Winrol is for intramuscular use only. It should not be given intravenously. Intramuscular injections should be given deep into the gluteal muscle. The suggested dosage for Winrol varies depending on age, sex and diagnosis of individual patients.

Supplied / Storage:
Winrol is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30°C and protected from light.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.

STANAPURE

Indications and usage:
Winrol is used in the treatment of hereditary angioedema, which causes episodic swelling of the face, extremities, genitals, lower leg, and throat. Winrol may decrease the frequency and severity of these attacks.

Gastrointestinal:
Gastrointestinal effects occurring during stanozolol (the active ingredient contained in Winrol) therapy include nausea and vomiting.

Dosage and administration:
Winrol is for intramuscular use only. It should not be given intravenously. Intramuscular injections should be given deep into the gluteal muscle. The suggested dosage for Winrol varies depending on age, sex and diagnosis of individual patients.

Supplied / Storage:
Winrol is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30°C and protected from light.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.



MASTER PRO

Each ml contains :
Drostanolone Propionate USP 100mg,
Oil Base q.s.

Indications and usage:
For use in females, for palliation of androgenresponsive, recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.

Contraindications:
1. Known hypersensitivity to the drug.
2. Males with carcinoma of the breast.
3. Males with known or suspected carcinoma of the prostate gland.
4. Women who are or who may become pregnant.
5. Patients with serious cardiac, hepatic or renal disease.

Drug interactions:
Androgens may increase Sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinaemia.
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

Overdosage:
Chronic ingestion of high doses of anabolic steroids can cause elevations in blood pressure, left ventricular hypertrophy and premature coronary artery disease.

Precautions/Warnings:
Women develop signs of virilism, with increased facial hair, male pattern baldness, acne, deepening of the voice, irregular menses and clitoral enlargement. Changes in the larynx in women caused by anabolic steroids can result in a hoarse, deep voice. The changes are irreversible!

Insulin resistance with a fall in:
Glucose tolerance and hypercholesterolaemia with a fall in high density lipoprotein cholesterol have been reported, we ne

Supplied / Storage:
Mastron is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° and protected from light.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.



TESTOC

Each ml contains :
Testosterone Cypionate USP 250mg,
Oil Base q.s.

Indications and usage:
Testosterone Cypionate is indicated for replacement therapy in males with conditions associated with symptoms of deficiency or absence of endogenous testosterone.
1. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral testis, orchitis, vanishing testis syndrome, or orchidectomy.
2. Hypogonadotropic hypogonadism (congenital or acquired) idiopathic gonadotropin or LH-RH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation

Contraindications:
1. Known hypersensitivity to the drug.
2. Males with carcinoma of the breast.
3. Males with known or suspected carcinoma of the prostate gland.
4. Women who are or who may become pregnant.
5. Patients with serious cardiac, hepatic or renal disease.

Warnings:
Hypocalcaemia may occur in immobilized patients. If this occurs, the drug should be discontinued. Prolonged use of high doses of androgens (principally the 17-delta alkyl-androgens) has been associated with development of hepatic adenomas, hepatocellular carcinoma and peliosis hepatis-all potentially life threatening complications.
Genitalic patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.

Overdosage:
There have been no reports of acute overdosage.

Precautions:
General: Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized. Testosterone Cypionate should not be used interchangeably with testosterone propionate because of differences in the duration of the action.

Information for patients: Patients should be instructed to report any of the following: nausea, vomiting, changes in skin colour, ankle swelling, too frequent or persistent erections of the penis. Laboratory tests: Haemoglobin and haematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long term androgen administration. Serum cholesterol may increase during androgen therapy. Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Supplied / Storage:
Testosterone Cypionate is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.



BOLDENUM

Each ml contains :
Boldenone Undecylenate 250mg,
Oil Base q.s.

Indications and usage:
Long acting anabolic steroid for animals. As an aid for treating debilitated horse when an improvement in weight, hair color or general physical condition is desired.

Drug interactions:
No known drug interactions.

Overdosage:
No information available.

Precautions:
EQUIPOSE should be used with caution in animals with heart liver or kidney Problems.

EQUIPOSE should not be used:
In animals with breast cancer or prostatic cancer.

Warnings:
EQUIPOSE should not be administered to horses intended for food purposes.

Supplied / Storage:
EQUIPOSE is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.



Each ml contains :
Methenolone Enanthate 100mg,
Oil Base q.s.

Indications and usage:
Diseases and conditions requiring high protein production to improve general condition of the patient.
Recovery period.
Postoperative treatment.
Cachexia.
Radiation and cytostatic therapy.
Advanced breast cancer and genital cancers in women.
Hematopoiesis disorders.
Long term corticoid treatment.

Contraindications:
Previous or present liver tumors, hyper sensitivity to active substance or its components.

Females:
Pregnancy.

Males:
Prostatic or breast carcinoma.

Doughinertations:
Primobolan may enhance effects of antidiabetics, cyclosporin, hydroxyrnone, warfarin. Resistance to the effects of neuromuscular blockers may occur.

Overdosage:
There have been no reports of acute overdosage.

Side Effects / Adverse reactions:
Fluid and electrolyte retention.
Psychiatric effects.
Hypocalcaemia.
Impaired glucose tolerance.
Increased bone growth and skeletal weight.

Warnings:
Virilization, amenorrhea, menstrual irregularities, suppressed lactation, increased libido.

Children:
Premature closure of epiphyses, stapes linear growth, virilization symptoms.

Precautions/Warnings:
If used Primobolan is applied during the first day of cycle, menstruation date may delay or women having irregular cycle.

Warnings:
Primobolan should be used with caution in patients with any of the following: heart failure, liver failure, kidney disease, allergy, enlarged prostate, high dosage, long term treatment for signs of infection, such as deepening of the voice, facial hair, acne, menstrual irregularity or clitoral enlargement.

Contraindications:
1. Known hypersensitivity to the drug.
2. Males with carcinoma of the prostate.
3. Males with known or suspected carcinoma of the prostate gland.
4. Pregnancy because of masculinization of the foetus.
5. Neutrosis or the nephrotic phase of nephritis.
6. Patients with serious cardiac, hepatic or renal disease.

Drug interactions:
Anticoagulants: Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring.

Overdosage:
There have been no reports of acute overdosage with the androgens.

Adverse reactions:
Hepatic: Cholestatic jaundice with, rarely hepatic necrosis and death. Hepatocellular neoplasms and peliosis hepatis have been reported in association with long-term use of androgenic anabolic steroids, particularly those that are 17-alpha-alkylated.

Genitourinary System:
In men: Priapism! Phallic enlargement and increased frequency of erections.

Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability.

In women: Clitoral enlargement, menstrual irregularities, in both sexes: increased or decreased libido.

CNS: Habituation, excitation, insomnia, depression.

Gastrointestinal: Nausea, vomiting, diarrhea.

Hematologic: bleeding in patients on concomitant antiplatelet therapy (see Precaution, Drug Interactions).

Arnyx: Deepening of the voice in women.

Hair: Hirsutism and male pattern baldness in women.

Skin: Acne (especially in women), acne vulgaris.

Skeletal: Premature closure of epiphyses in children (see Precaution, Pediatric Use).

Fluid and electrolyte: Edema, retention of serum electrolytes (sodium chloride, potassium phosphate, calcium).

Metabolic/endocrine: Decreased glucose tolerance, increased serum levels of low-density lipoproteins and decreased levels of high-density lipoproteins, increased creatine and creatinine excretion, increased serum levels of creatine phosphokinase.

Warnings:
Chronic ingestion of high doses of anabolic steroids can cause elevations in blood pressure, left ventricular hypertrophy and premature coronary artery disease.

Insulin resistance with a fall in:
Glucose tolerance and hypercholesterolaemia with a fall in high density lipoprotein cholesterol have been reported, we ne

Supplied / Storage:
Deca Durabolin is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.

NANOPURE

Each ml contains :
Nandrolone Decanoate USP 250mg,
Oil Base q.s.

Indications and usage:
Deca Durabolin is indicated for the management of the anemia of renal insufficiency and iron deficiency.

Contraindications:
1. Known hypersensitivity to the drug.
2. Males with carcinoma of the prostate.
3. Males with known or suspected carcinoma of the prostate gland.
4. Pregnancy because of masculinization of the foetus.
5. Neutrosis or the nephrotic phase of nephritis.
6. Patients with serious cardiac, hepatic or renal disease.

Drug interactions:
Anticoagulants: Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring.

Overdosage:
There have been no reports of acute overdosage with the androgens.

Adverse reactions:
Hepatic: Cholestatic jaundice with, rarely hepatic necrosis and death. Hepatocellular neoplasms and peliosis hepatis have been reported in association with long-term use of androgenic anabolic steroids, particularly those that are 17-alpha-alkylated.

Genitourinary System:
In men: Priapism! Phallic enlargement and increased frequency of erections.

Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability.

In women: Clitoral enlargement, menstrual irregularities, in both sexes: increased or decreased libido.

CNS: Habituation, excitation, insomnia, depression.

Gastrointestinal: Nausea, vomiting, diarrhea.

Hematologic: bleeding in patients on concomitant antiplatelet therapy (see Precaution, Drug Interactions).

Arnyx: Deepening of the voice in women.

Hair: Hirsutism and male pattern baldness in women.

Skin: Acne (especially in women), acne vulgaris.

Skeletal: Premature closure of epiphyses in children (see Precaution, Pediatric Use).

Fluid and electrolyte: Edema, retention of serum electrolytes (sodium chloride, potassium phosphate, calcium).

Metabolic/endocrine: Decreased glucose tolerance, increased serum levels of low-density lipoproteins and decreased levels of high-density lipoproteins, increased creatine and creatinine excretion, increased serum levels of creatine phosphokinase.

Warnings:
Chronic ingestion of high doses of anabolic steroids can cause elevations in blood pressure, left ventricular hypertrophy and premature coronary artery disease.

Insulin resistance with a fall in:
Glucose tolerance and hypercholesterolaemia with a fall in high density lipoprotein cholesterol have been reported, we ne

Supplied / Storage:
Deca Durabolin is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.

TREN ACE

Each ml contains :
Trenbolone Acetate USP 100mg,
Oil Base q.s.

Indications and usage:
Fast acting anabolic steroid for animals with strong androgenic and anabolic activity. For increased rate of weight gain and improved feed efficiency.

Drug interactions:
No known drug interactions.

Overdosage:
No information available.

Precautions:
Trenbolone Acetate should be used with caution in animals with heart, liver, or kidney problems.

Warnings:
Not to be used in animals intended for subsequent breeding, or in dairy animals.

Supplied / Storage:
Trenbolone Acetate is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.



TREN EN

Each ml contains :
Trenbolone Enanthate USP 200mg,
Oil Base q.s.

Indications and usage:
Fast acting anabolic steroid for animals with strong androgenic and anabolic activity. For increased rate of weight gain and improved feed efficiency.

Drug interactions:
No known drug interactions.

Overdosage:
No information available.

Precautions:
Trenbolone Acetate should be used with caution in animals with heart, liver, or kidney problems.

Warnings:
Not to be used in animals intended for subsequent breeding, or in dairy animals.

Supplied / Storage:
Trenbolone Acetate is supplied in 10 x 1ml ampoules. Ampoules should be stored at controlled room temperatures below 30° C and protected from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warning and shaking the ampoules should redissolve any crystals that may have formed during storage at temperature lower than recommended. If it has expired or is damaged, return to your pharmacist.

Keep out of the reach and sight of children.

